These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 378855)

  • 21. Immunoprotective extracellular polysaccharides of Klebsiella aerogenes capsular type K1, expressed in Escherichia coli.
    Roe EA; Jones RJ; Saunders JR
    FEMS Microbiol Immunol; 1989 Apr; 1(5):253-61. PubMed ID: 2517220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seroepidemiology of Klebsiella bacteremic isolates and implications for vaccine development.
    Cryz SJ; Mortimer PM; Mansfield V; Germanier R
    J Clin Microbiol; 1986 Apr; 23(4):687-90. PubMed ID: 3517058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoprotective activity of ribosomes from Haemophilus influenzae.
    Lynn M; Tewari RP; Solotorovsky M
    Infect Immun; 1977 Feb; 15(2):453-60. PubMed ID: 300360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans.
    Cryz SJ; Fürer E; Germanier R
    J Infect Dis; 1985 Apr; 151(4):665-71. PubMed ID: 3882856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization with the outer membrane proteins OmpK17 and OmpK36 elicits protection against Klebsiella pneumoniae in the murine infection model.
    Hussein KE; Bahey-El-Din M; Sheweita SA
    Microb Pathog; 2018 Jun; 119():12-18. PubMed ID: 29626658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis.
    Nemeth J; Lee JC
    Infect Immun; 1995 Feb; 63(2):375-80. PubMed ID: 7821999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of fatal experimental burn-wound sepsis due to Klebsiella pneumoniae KP1-O by immunization with homologous capsular polysaccharide.
    Cryz SJ; Fürer E; Germanier R
    J Infect Dis; 1984 Dec; 150(6):817-22. PubMed ID: 6389718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the role of the pneumococcal Forssman antigen (F-polysaccharide) in the cross-serotype protection induced by pneumococcal subcellular preparations.
    Au CC; Einsenstein TK
    Infect Immun; 1981 Jan; 31(1):169-73. PubMed ID: 7216443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3.
    Snippe H; van Houte AJ; van Dam JE; De Reuver MJ; Jansze M; Willers JM
    Infect Immun; 1983 Jun; 40(3):856-61. PubMed ID: 6852923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surface exposure of O1 serotype lipopolysaccharide in Klebsiella pneumoniae strains expressing different K antigens.
    Tomás JM; Camprubi S; Merino S; Davey MR; Williams P
    Infect Immun; 1991 Jun; 59(6):2006-11. PubMed ID: 1709919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Protective activity of a cell-free Klebsiella vaccine in relation to different Klebsiella pneumoniae serovars].
    Kurbatova EA; Egorova NB; Kiseleva BS
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Aug; (8):80-3. PubMed ID: 6385585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Capsular polysaccharide of Klebsiella pneumoniae. II. Immunogenic properties].
    Alcántar-Curiel MD; Martínez-Ramos A; García-Latorre E
    Rev Latinoam Microbiol; 1993; 35(1):109-15. PubMed ID: 8140330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purification and vaccine potential of Klebsiella capsular polysaccharides.
    Cryz SJ; Fürer E; Germanier R
    Infect Immun; 1985 Oct; 50(1):225-30. PubMed ID: 4044036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance to Klebsiella pneumoniae and the importance of two bacterial antigens.
    Cooper JM; Rowley D
    Aust J Exp Biol Med Sci; 1982 Dec; 60(6):629-41. PubMed ID: 6820634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A promising bioconjugate vaccine against hypervirulent
    Feldman MF; Mayer Bridwell AE; Scott NE; Vinogradov E; McKee SR; Chavez SM; Twentyman J; Stallings CL; Rosen DA; Harding CM
    Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18655-18663. PubMed ID: 31455739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purified capsular polysaccharide-induced immunity to Staphylococcus aureus infection.
    Lee JC; Perez NE; Hopkins CA; Pier GB
    J Infect Dis; 1988 Apr; 157(4):723-30. PubMed ID: 3346565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination against Klebsiella aerogenes.
    Roe EA; Jones RJ
    J Hyg (Lond); 1984 Oct; 93(2):355-63. PubMed ID: 6389699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protection of mice by a pseudodiffuse strain of Staphylococcus aureus possessing polyvalent capsular type antigen.
    Chomarat M; Ichiman Y; Yoshida K
    J Med Microbiol; 1989 Feb; 28(2):129-36. PubMed ID: 2915365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection against fatal Klebsiella pneumoniae sepsis in the squirrel monkey Saimiri sciureus after immunization with a capsular polysaccharide vaccine.
    Postal JM; Gysin J; Crenn Y
    Ann Inst Pasteur Immunol; 1988; 139(4):401-7. PubMed ID: 3048318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serotype-nonspecific protection induced by ribonucleic acid isolated from the ribosomal vaccine of Pseudomonas aeruginosa.
    Gonggrijp R; Mullers WJ; van Boven CP
    Infect Immun; 1981 Jul; 33(1):178-85. PubMed ID: 6167518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.